Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 9:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 560 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Antiretroviral therapy (ART) Clear all
Completed No phase listed Observational Accepts healthy volunteers

Observational Study of Blood Treated With Cytolin

NCT01048372
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
CytoDyn, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 21, 2013 · Synced Oct 5, 2026, 9:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Metabolic Effects of Protease Inhibitors in HIV Infected Children

NCT00004739
View directory record Official record
Conditions
HIV Infections
Interventions
Antiretroviral therapy
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
7 Years to 18 Years
Healthy volunteers
Accepts healthy volunteers
U.S. locations
2
States / cities
Houston, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 5, 2026, 9:33 AM EDT
Completed No phase listed Observational

HIV in Specific Parts of the Body of Patients Who Are Changing or Starting Potent Anti-HIV Drugs

NCT00007488
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
23
States / cities
Los Angeles, California • Menlo Park, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2013 · Synced Oct 5, 2026, 9:33 AM EDT
Recruiting Phase 1 Interventional

Dasatinib for HIV-1 Reservoir Reduction

NCT07342491
View directory record Official record
Conditions
HIV Infections
Interventions
Dasatinib, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Chicago, Illinois • Cleveland, Ohio • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 5, 2026, 9:33 AM EDT
Completed Phase 1 Interventional

HIV-1 Specific T -Cells (HST-NEETs) for HIV-Infected Individuals

NCT03485963
View directory record Official record
Conditions
HIV Infections
Interventions
HST-NEETs
Biological
Lead sponsor
Catherine Bollard
Other
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
3
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 5, 2026, 9:33 AM EDT
Completed Phase 2 Interventional Results available

VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living With HIV-1

NCT06214052
View directory record Official record
Conditions
HIV Infections
Interventions
VH4524184, Matching Placebo, Antiretroviral therapy
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
5
States / cities
Bakersfield, California • Los Angeles, California • West Hollywood, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2025 · Synced Oct 5, 2026, 9:33 AM EDT
Completed Phase 4 Interventional Results available

Strategic Timing of Antiretroviral Treatment

NCT00867048
View directory record Official record
Conditions
HIV Infection
Interventions
All licensed antiretroviral medications
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
4,688 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2022
U.S. locations
55
States / cities
Alhambra, California • Los Angeles, California • San Diego, California + 37 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Oct 5, 2026, 9:33 AM EDT
Completed Phase 3 Interventional

A Phase IIIB Study Evaluating the Effect on Serum Lipids Following a Switch to Atazanavir in HIV Infected Subjects Evidencing Virologic Suppression on Their First PI-Based Antiretroviral Therapy

NCT00067782
View directory record Official record
Conditions
HIV Infections
Interventions
Atazanavir (immediate switch), Atazanavir (Week 24 switch)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
19
States / cities
Phoenix, Arizona • West Hollywood, California • Washington D.C., District of Columbia + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2011 · Synced Oct 5, 2026, 9:33 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Incidence and Severity of Drug Interactions Before and After Switching Antiretroviral Therapy to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Treatment Experienced Patients

NCT03789968
View directory record Official record
Conditions
HIV/AIDS
Interventions
bictegravir/emtricitabine/tenofovir alafenamide
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
411 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 5, 2026, 9:33 AM EDT
Completed Phase 2 Interventional Results available

Phase II/III Study Evaluating the Effect of IL-2 on Preservation of the CD4 T-Lymphocytes After Interruption of Antiretroviral Treatment in HIV-Infected Patients With CD4 T-Lymphocyte Count Greater Than 500 Cells/mm3 Who Received Antiretroviral Tx

NCT00071890
View directory record Official record
Conditions
HIV Infections
Interventions
Interleukin 2, HAART, Treatment interruption
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2010 · Synced Oct 5, 2026, 9:33 AM EDT
Completed Phase 1 Interventional

A Comparative Study of Combination Antiretroviral Therapy in Children and Adolescents With Advanced HIV Disease

NCT00000814
View directory record Official record
Conditions
HIV Infections
Interventions
Nevirapine, Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 20 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
65
States / cities
Birmingham, Alabama • La Jolla, California • Long Beach, California + 40 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 5, 2026, 9:33 AM EDT
Completed Phase 2 Interventional Results available

Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine

NCT01641809
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
GSK1265744 10 mg, GSK1265744 30 mg, GSK1265744 60 mg, Efavirenz 600 mg, Rilpivirine 25 mg, Placebo, Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 35 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2020 · Synced Oct 5, 2026, 9:33 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in the Central Nervous System in HIV-1 Infected ART-naive Subjects

NCT01499199
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Dolutegravir
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Los Angeles, California • San Diego, California • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 25, 2015 · Synced Oct 5, 2026, 9:33 AM EDT
Completed Phase 2 Interventional

Safety and Effectiveness of Adding Either an HIV Vaccine, Interleukin-2, or Both to a Patient's Anti-HIV Drug Combination

NCT00006291
View directory record Official record
Conditions
HIV Infections
Interventions
ALVAC(2)120(B,MN)GNP (vCP1452), Aldesleukin
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
25
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 5, 2026, 9:33 AM EDT
Not listed Phase 1 Interventional

A Phase 1 Safety and Immunogenicity Study of the Epitope Based DNA Vaccine (EP HIV-1090) in HIV-1 Infected Individuals Receiving Antiretroviral Therapy (ART)

NCT00532974
View directory record Official record
Conditions
HIV Infections
Interventions
EP1090
Biological
Lead sponsor
Epimmune
Industry
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
West Hollywood, California • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 24, 2007 · Synced Oct 5, 2026, 9:33 AM EDT
Completed Not applicable Interventional Results available

Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy and Switch to an Elvitegravir-based Regimen

NCT01929759
View directory record Official record
Conditions
HIV Disease
Interventions
Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 28, 2017 · Synced Oct 5, 2026, 9:33 AM EDT
Completed Phase 1 Interventional

Safety of FMT Using Oral Encapsulated PRIM-DJ2727 in HIV

NCT03329560
View directory record Official record
Conditions
HIV-1-infection
Interventions
Oral fecal microbiota transplantation
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 27, 2020 · Synced Oct 5, 2026, 9:33 AM EDT
Completed No phase listed Observational

Obesity in HIV After Antiretroviral Therapy

NCT01461876
View directory record Official record
Conditions
HIV, AIDS, Obesity
Interventions
antiretroviral therapy
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Oct 5, 2026, 9:33 AM EDT
Completed Not applicable Interventional Results available

Living Well Project for Persons With AIDS

NCT01848483
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome (AIDS)
Interventions
AIDS EPC Package plus MI, Standard of Care (SOC)
Behavioral · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 30, 2019 · Synced Oct 5, 2026, 9:33 AM EDT
Completed Phase 2 Interventional

Interleukin-12 Following Chemotherapy in Treating Patients With Refractory HIV-Associated Non-Hodgkin's Lymphoma

NCT00003575
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, recombinant interleukin-12, etoposide, ifosfamide
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2013 · Synced Oct 5, 2026, 9:33 AM EDT
Terminated Phase 2 Interventional Results available

Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals

NCT04272242
View directory record Official record
Conditions
HIV Infection, LTBI
Interventions
Dolutegravir (DTG), Isoniazid (INH), Rifapentine (RPT), Antiretroviral Therapy (ART), Pyridoxine (Vitamin B6)
Drug · Dietary Supplement
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
2
States / cities
San Francisco, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 5, 2026, 9:33 AM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetic Study to Evaluate Double-Dose Levonorgestrel Emergency Contraception in Combination With Efavirenz-Based Antiretroviral Therapy or Rifampicin-Containing Anti-Tuberculosis Therapy

NCT03819114
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Levonorgestrel (LNG)
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
16 Years and older · Female only
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
7
States / cities
Chicago, Illinois • New York, New York • Chapel Hill, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2021 · Synced Oct 5, 2026, 9:33 AM EDT
Completed Not applicable Interventional

Enhancing Recruitment, Linkage to Care and Treatment for HIV-Infected MSM in the United States

NCT02663219
View directory record Official record
Conditions
HIV
Interventions
Intervention
Behavioral
Lead sponsor
HIV Prevention Trials Network
Network
Eligibility
16 Years and older · Male only
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
4
States / cities
Birmingham, Alabama • Atlanta, Georgia • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Oct 5, 2026, 9:33 AM EDT
Completed Phase 3 Interventional

Double-Blind Study of Timunox (Thymopentin) in Asymptomatic HIV-Infected Patients Receiving Either Mono (AZT or ddI) or Combination (AZT / ddI or AZT / ddC) Anti-Retroviral Therapy

NCT00002109
View directory record Official record
Conditions
HIV Infections
Interventions
Thymopentin, Stavudine, Zidovudine, Zalcitabine, Didanosine
Drug
Lead sponsor
Immunobiology Research Institute
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
48
States / cities
Phoenix, Arizona • Irvine, California • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 5, 2026, 9:33 AM EDT